CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by CRISPR Therapeutics AG insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $1.41M in total
- Insiders trading
- 2
- Net value
- −$1.41M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for CRISPR Therapeutics AG, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kasinger James R. | General Counsel and Secretary | 94,784 | Sep 24, 2026 | 8 |
| Behbahani Ali | Director | 16,637 | Sep 21, 2026 | 3 |
| Prasad Raju | Chief Financial Officer | 14,815 | Aug 11, 2026 | 8 |
| Mahatme Sandesh | Director | – | Jun 9, 2026 | 1 |
| Fardis Maria | Director | – | Jun 9, 2026 | 1 |
| George Simeon | Director | 1,730,179Indirect | Jun 9, 2026 | 1 |
| Greene John | Director | 7,000 | Jun 9, 2026 | 1 |
| High Katherine A | Director | – | Jun 9, 2026 | 1 |
| Morrison Briggs | Director | – | Jun 9, 2026 | 1 |
| Treco Douglas A | Director | 22,000 | Jun 9, 2026 | 1 |
| Fleming Harold Edward | Director | – | Jun 9, 2026 | 1 |
| Rommel Christian | Director | – | Jun 9, 2026 | 1 |
| Patel Naimish | Chief Medical Officer | 19,357 | Jun 2, 2026 | 6 |
| Kulkarni Samarth | Chief Executive Officer | 255,501 | Mar 24, 2026 | 9 |
| Bruno Julianne | Chief Operating Officer | 10,544 | Mar 24, 2025 | 0 |
| Morrow Phuong Khanh | Chief Medical Officer | 4,411 | Oct 17, 2023 | 0 |
| Smith Brendan | Chief Financial Officer | 5,072 | Feb 22, 2023 | 0 |
| Klein Lawrence Otto | CBO & COO | 26,797 | Aug 18, 2022 | 0 |
| Bolzon Bradley J PhD | Director | 148,831Indirect | Jun 10, 2022 | 0 |
| Ho Tony W | Executive VP, Head of R&D | 52,364 | Dec 7, 2021 | 0 |
| Tomsicek Michael John | Chief Financial Officer | 1,891 | Aug 10, 2021 | 0 |
| Novak Rodger | President | 573,007 | Jul 1, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 21, 2024 (view filing) | Feb 20 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −6.37K | $79.67 | −$507.5K | −3.2%194.3K after | |
| Feb 16, 2024 (view filing) | Feb 15 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −20.0K | $80.36 | −$1.61M | −9.6%187.4K after | 3 lots10b5-1 |
| Jan 31, 2024 (view filing) | Jan 29 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −50.0K | $60.51 | −$3.03M | −21.1%187.4K after | 2 lots10b5-1 |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −20.0K | $62.50 | −$1.25M | −9.6%187.4K after | 10b5-1 |
| Jun 1, 2023 (view filing) | May 30 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $64.87 | −$1.62M | −6.1%387.4K after | 4 lots10b5-1 |
| Apr 27, 2023 (view filing) | Apr 25 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $50.67 | −$1.27M | −6.1%387.4K after | 2 lots10b5-1 |
| Mar 31, 2023 (view filing) | Mar 29 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $44.46 | −$1.11M | −6.1%387.4K after | 2 lots |
| Mar 1, 2023 (view filing) | Feb 27 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $48.25 | −$1.21M | −6.2%376.0K after | 3 lots |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $51.47 | −$1.29M | −6.3%369.1K after | 2 lots |
| Dec 30, 2022 (view filing) | Dec 28 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $40.93 | −$1.02M | −6.3%369.1K after | 2 lots |
| Nov 30, 2022 (view filing) | Nov 28 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $54.03 | −$1.35M | −7.9%290.3K after | 3 lots |
| Oct 28, 2022 (view filing) | Oct 26 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $54.81 | −$1.37M | −7.9%290.3K after | 4 lots |
| Sep 30, 2022 (view filing) | Sep 28 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $64.61 | −$1.62M | −7.9%290.3K after | 2 lots |
| Aug 31, 2022 (view filing) | Aug 29 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $66.85 | −$1.67M | −7.9%290.3K after | 3 lots |
| Jul 29, 2022 (view filing) | Jul 27 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $75.91 | −$1.90M | −7.9%290.3K after | 6 lots |
| Jul 1, 2022 (view filing) | Jun 29 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −25.0K | $61.59 | −$1.54M | −7.9%290.3K after | 2 lots |
| Aug 10, 2021 (view filing) | Aug 6 | 4 days | Tomsicek Michael JohnChief Financial Officer | SSale | −25.0K | $138.52 | −$3.46M | −93.0%1.89K after | 2 lots |
| Aug 6, 2021 (view filing) | Aug 4 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −1.50K | $125.02 | −$187.5K | −0.8%187.7K after | |
| Aug 6, 2021 (view filing) | Aug 5 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −28.5K | $128.98 | −$3.68M | −13.2%187.7K after | 5 lots |
| Jul 21, 2021 (view filing) | Jul 19 | 2 days | Bolzon Bradley J PhDDirector | SSale | −10.0K | $126.44 | −$1.26M | −6.3%148.8K after | 4 lots |
| Jul 1, 2021 (view filing) | Jun 30 | 1 day | Novak RodgerPresident | SSale | −25.0K | $165.00 | −$4.13M | −4.2%573.0K after |